A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.

Trial Profile

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Bortezomib; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2011 Actual patient number is 55 according to ClinicalTrials.gov.
    • 04 Apr 2011 End date added from ClinicalTrials.gov
    • 04 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top